# language_name_wals:	English
# language_name_glotto:	English
# ISO_6393:	eng
# year_composed:	NA
# year_published:	NA
# mode:	written
# genre_broad:	technical
# genre_narrow:	NA
# writing_system:	Latn
# special_characters:	NA
# short_description:	EMEA
# source:	https://object.pouta.csc.fi/OPUS-EMEA/v3/raw/en.zip
# copyright_short:	http://opus.nlpl.eu/EMEA.php
# copyright_long:	http://opus.nlpl.eu/EMEA.php J. Tiedemann, 2012, Parallel Data, Tools and Interfaces in OPUS. In Proceedings of the 8th International Conference on Language Resources and Evaluation (LREC 2012)
# sample_type:	whole
# comments:	NA

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1/ 16 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza, suspension for injection, for horses
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Per dose of 1 ml:
Active substances Purified haemagglutinin subunits from equine influenza viruses:
A/ equine-1/ Prague/ 1/ 56 A/ equine-2/ Newmarket/ 1/ 93 A/ equine-2/ Newmarket/ 2/ 93
100 AU1 50 AU 50 AU
Adjuvant
Purified Saponin Cholesterol Phosphatidylcholine
375 micrograms 125 micrograms 62.5 micrograms
Excipient Thiomersal traces
For full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection
4.
CLINICAL PARTICULARS
4.1 Target species
Horses
4.2 Indications for use, specifying the target species
Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection.
Influenza Onset of Duration
immunity: of immunity:
2 weeks after the primary vaccination course 5 months after the primary vaccination course 12 months after the first revaccination
4.3
Contraindications
None
1 Antigenic units
2/ 16 4.4 Special warnings
Foals should not be vaccinated before the age of 6 months, especially when born to mares that were revaccinated in the last two months of gestation, because of possible interference by maternally derived antibodies.
4.5 Special precautions for use
Only healthy animals should be vaccinated.
Special precautions for use in animals
Not applicable
Special precautions to be taken by the person administering the medicinal product to animals
In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician.
4.6 Adverse reactions (frequency and seriousness)
A diffuse hard or soft swelling (max. diameter 5 cm) may occur at the injection site, regressing within 2 days.
Pain at the injection site can occur in rare cases, which may result in temporary functional discomfort (stiffness).
In very rare cases, fever, sometimes accompanied by lethargy and inappetence, may occur for 1 day, and up to 3 days in exceptional circumstances.
4.7 Use during pregnancy, lactation or lay
Can be used during pregnancy and lactation.
4.8 Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other vaccine.
It is therefore recommended that no other vaccines should be administered concurrently or simultaneously.
4.9 Amounts to be administered and administration route
Intramuscular use
Vaccination schedule:
Primary vaccination course
Administer one dose (1ml), by intramuscular injection, according to the following schedule: • Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later
Revaccination
The first revaccination (third dose) is given 5 months after the primary vaccination course.
This revaccination results in immunity to equine influenza lasting at least 12 months.
The second revaccination is given 12 months after the first revaccination.
The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains A/ equi 1/ Prague 56, A/ equi 2/ Newmarket-1/ 93 and A/ equi 2/ Newmarket-2/ 93, is recommended to maintain immunity levels for the influenza component (see scheme).
3/ 16 In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 6 months of age and 4 weeks later).
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Following the administration of a double dose of vaccine, no side-effects other than those described under 4.6 have been observed except for some depression at the day of vaccination
4.11 Withdrawal period(s)
Zero days
5.
IMMUNOLOGICAL PROPERTIES
To stimulate active immunity against Equine influenza ATC-vet code:
QI05AA01
6.
PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Purified Saponin, Cholesterol, Phosphatidylcholine, Thiomersal traces
6.2 Incompatibilities
Do not mix with any other vaccine or immunological product.
6.3 Shelf life
2 years
6.4 Special precautions for storage
Store at 2-8°C, protected from light.
Do not freeze.
6.5 Nature and composition of immediate packaging
Type I glass vial closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.
Type I glass pre-filled syringe, containing a plunger with a halogenobutyl end and closed with a halogenobutyl stopper.
4/ 16 Package size:
Cardboard box with 10 glass vials of 1 ml.
Cardboard box(es) with 1, 5 or 10 pre-filled syringes with needles.
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7.
MARKETING AUTHORISATION HOLDER
Intervet International B. V.
Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
8.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 05/ 056/ 001-004
9.
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
08/ 07/ 2005
10.
DATE OF REVISION OF THE TEXT
23/ 03/ 2009
PROHIBITION OF SALE, SUPPLY AND/ OR USE
Not applicable.
5/ 16 ANNEX II
A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY AND USE
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
D.
STATEMENT OF THE MRLs
6/ 16 A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer of the biological active substance
Laboratorios Intervet, S. A.
Poligono El Montalvo 37080 Salamanca Spain
Name and address of the manufacturer responsible for batch release
Intervet International B. V.
Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY AND USE
Veterinary medicinal product subject to prescription.
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
Not applicable
D.
STATEMENT OF THE MRLs
The active substance being a principle of biological origin intended to produce active immunity is not in the scope of Council Regulation (EEC) 2377/ 90.
The MRL status of the excipients is as follows:
Substance Saponin
MRL status Annex II for all food producing species (under Quillaia saponins)
Comments Commission Regulation (EEC) No 1433/ 96
Sodium phosphate (Na2HPO4)
Covered by Annex II entry for authorised food additives with an E number (E339)
Commission Regulation (EEC) No 2034/ 96
Potassium phosphate (KH2PO4)
Annex II for all food producing species (approved as food additives with an E number (E340))
Commission Regulation (EEC) No 2034/ 96
Sodium chloride (NaCl)
Annex II for all food producing species
Commission Regulation (EEC) No 2796/ 95
Magnesium chloride (MgCl2) Calcium chloride (CaCl2)
Annex II for all food producing species Annex II for all food producing species
Commission Regulation (EEC) No 2796/ 95 Commission Regulation (EEC) No 1102/ 95
7/ 16 ANNEX III
LABELLING AND PACKAGE LEAFLET
8/ 16 A.
LABELLING
9/ 16 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Per dose of 1 ml:
A/ equine-1/ Prague 56 (100 AU), A/ equine-2/ Newmarket/ 1/ 93 (50 AU), A/ equine 2/ Newmarket/ 2/ 93 (50 AU).
3.
PACKAGE SIZE
1, 5 or 10 x 1 dose
4.
TARGET SPECIES
Horses
5.
INDICATION(S)
Active immunisation of horses against equine influenza.
6.
METHODS AND ROUTE OF ADMINISTRATION
i. m. use
7.
WITHDRAWAL PERIOD
Zero days
8.
EXPIRY DATE
{month/ year}
9.
SPECIAL STORAGE CONDITIONS
Store at 2-8 °C, protected from light.
Do not freeze.
10/ 16 10.
THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only Veterinary medicinal product subject to prescription.
11.
THE WORDS "KEEP OUT OF REACH AND SIGHT OF CHILDREN"
Keep out of reach and sight of children
12.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Intervet International B. V.
13.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 05/ 056/ 001-004
14.
MANUFACTURER'S BATCH NUMBER
11/ 16 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza
2.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
1 dose
3.
ROUTE OF ADMINISTRATION
i. m.
4.
BATCH NUMBER
{batch no.}
5.
EXPIRY DATE
{month/ year}
12/ 16 B.
PACKAGE LEAFLET
13/ 16 PACKAGE LEAFLET FOR:
Equilis Prequenza, suspension for injection, for horses
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE IN THE EEA, IF DIFFERENT
Intervet International B. V.
Wim de Körverstraat 35 NL-5831 AN Boxmeer The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Equilis Prequenza, suspension for injection, for horses
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
Per dose of 1 ml:
Active substance Purified haemagglutinin subunits from equine influenza viruses:
A/ equine-1/ Prague/ 1/ 56 A/ equine-2/ Newmarket/ 1/ 93 A/ equine-2/ Newmarket/ 2/ 93
100 AU2 50 AU 50 AU
Adjuvant
Purified saponin Cholesterol Phosphatidylcholine
375 micrograms 125 micrograms 62.5micrograms
Excipient Thiomersal traces
4.
INDICATION(S)
Active immunisation of horses from 6 months of age against equine influenza to reduce clinical signs and virus excretion after infection.
Influenza Onset of immunity:
Duration of immunity:
2 weeks after the primaryvaccination course 5 months after the primaryvaccination course 12 months after the first revaccination
5.
CONTRAINDICATIONS
None
2 Antigenic units
14/ 16 6.
ADVERSE REACTIONS
A diffuse hard or soft swelling (max. diameter 5 cm) may occur at the injection site, regressing within 2 days.
Pain at the injection site can occur in rare cases which may result in temporary functional discomfort (stiffness).
In very rare cases, fever, sometimes accompanied by lethargy and inappetence, may occur for 1 day, for up to 3 days in exceptional circumstances.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
7.
TARGET SPECIES
Horses
8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
1 ml.
Intramuscular use
Vaccination schedule:
Primary vaccination course
Administer one dose (1ml), by intramuscular injection, according to the following schedule: • Primary vaccination course: first injection from 6 months of age, second injection 4 weeks later
Revaccination
The first revaccination (third dose) is given 5 months after the primary vaccination course.
This revaccination results in immunity to equine influenza lasting at least 12 months.
The second revaccination is given 12 months after the first revaccination.
The alternate use, at 12 months interval, of a suitable vaccine against equine influenza, containing the strains A/ equi 1/ Prague 56, A/ equi 2/ Newmarket-1/ 93 and A/ equi 2/ Newmarket-2/ 93, is recommended to maintain immunity levels for the influenza component (see scheme).
In case of increased infection risk or insufficient colostrum intake, an additional initial injection can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 6 months of age and 4 weeks later).
9.
ADVICE ON CORRECT ADMINISTRATION
15/ 16 Allow the vaccine to reach a temperature of 15°C - 25°C.
Administer 1 ml of vaccine i. m..
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other vaccine.
It is therefore recommended that no other vaccines should be administered concurrently or simultaneously.
10.
WITHDRAWAL PERIOD
Zero days
11.
SPECIAL STORAGE PRECAUTIONS
Keep out of the reach and sight of children.
Store at 2-8°C, protected from light.
Do not freeze.
Do not use after the expiry date stated on the label.
12.
SPECIAL WARNING(S)
Foals should not be vaccinated before the age of 6 months, especially when born to mares that were revaccinated in the last two months of gestation, because of possible interference by maternally derived antibodies.
Only healthy animals should be vaccinated.
In case of accidental self-injection, seek medical advice immediately and show this package insert or the label to the physician.
Do not mix with any other vaccine or immunological product.
13.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
14.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
23/ 03/ 2009
15.
OTHER INFORMATION
Cardboard box with 10 glass vials of 1 ml.
Cardboard box(es) with 1, 5 or 10 pre-filled syringes with needles.
Not all pack sizes may be marketed.
16/ 16